High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count > 600 x 109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable

被引：46

作者：

Gattermann, Norbert ^{[1
]}

Billiet, Johan ^{[1
]}

Kronenwett, Ralf ^{[1
]}

Zipperer, Esther ^{[1
]}

Germing, Ulrich ^{[1
]}

Nollet, Friedel ^{[1
]}

Criel, Arnold ^{[1
]}

Selleslag, Dominik ^{[1
]}

机构：

[1] Univ Klinikum Dusseldorf, Klin Hamatol Onkol & Klin Immunol, D-40591 Dusseldorf, Germany

来源：

BLOOD | 2007年 / 109卷 / 03期

关键词：

D O I：

10.1182/blood-2006-05-022491

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1334 / 1335

页数：2

共 10 条

[1]

BAIN B, 2001, WHO CLASSIFICATION T, P58

[2] Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].

Baxter, EJ ;

Scott, LM ;

Campbell, PJ ;

East, C ;

Fourouclas, N ;

Swanton, S ;

Vassiliou, GS ;

Bench, AJ ;

Boyd, EM ;

Curtin, N ;

Scott, MA ;

Erber, WN ;

Green, AR .

LANCET, 2005, 365 (9464) :1054-1061

[3] The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS) [J].

Boissinot, Marjorie ;

Garand, Richard ;

Hamidou, Mohamed ;

Hermouet, Sylvie .

BLOOD, 2006, 108 (05) :1781-1782

[4] A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera [J].

James, C ;

Ugo, V ;

Le Couédic, JP ;

Staerk, J ;

Delhommeau, F ;

Lacout, C ;

Garçon, L ;

Raslova, H ;

Berger, R ;

Bennaceur-Griscelli, A ;

Villeval, JL ;

Constantinescu, SN ;

Casadevall, N ;

Vainchenker, W .

NATURE, 2005, 434 (7037) :1144-1148

[5] A gain-of-function mutation of JAK2 in myeloproliferative disorders [J].

Kralovics, R ;

Passamonti, F ;

Buser, AS ;

Teo, S ;

Tiedt, R ;

Passweg, JR ;

Tichelli, A ;

Cazzola, M ;

Skoda, RC .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (17) :1779-1790

[6] Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis [J].

Levine, RL ;

Wadleigh, M ;

Cools, J ;

Ebert, BL ;

Wernig, G ;

Huntly, BJP ;

Boggon, TJ ;

Wlodarska, L ;

Clark, JJ ;

Moore, S ;

Adelsperger, J ;

Koo, S ;

Lee, JC ;

Gabriel, S ;

Mercher, T ;

D'Andrea, A ;

Fröhling, S ;

Döhner, K ;

Marynen, P ;

Vandenberghe, P ;

Mesa, RA ;

Tefferi, A ;

Griffin, JD ;

Eck, MJ ;

Sellers, WR ;

Meyerson, M ;

Golub, TR ;

Lee, SJ ;

Gilliland, DG .

CANCER CELL, 2005, 7 (04) :387-397

[7]

Remacha AF, 2006, HAEMATOLOGICA, V91, P719

[8] The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes [J].

Steensma, DP ;

Dewald, GW ;

Lasho, TL ;

Powell, HL ;

McClure, RF ;

Levine, RL ;

Gilliland, DG ;

Tefferi, A .

BLOOD, 2005, 106 (04) :1207-1209

[9] Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation [J].

Szpurka, Hadrian ;

Tiu, Ramon ;

Murugesan, Gurunathan ;

Aboudola, Samer ;

Hsi, Eric D. ;

Theil, Karl S. ;

Sekeres, Mikkael A. ;

Maciejewski, Jaroslaw P. .

BLOOD, 2006, 108 (07) :2173-2181

[10] Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features [J].

Wang, S. A. ;

Hasserjian, R. P. ;

Loew, J. M. ;

Sechman, E. V. ;

Jones, D. ;

Hao, S. ;

Liu, Q. ;

Zhao, W. ;

Mehdi, M. ;

Galili, N. ;

Woda, B. ;

Raza, A. .

LEUKEMIA, 2006, 20 (09) :1641-1644

← 1 →

High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count &gt; 600 x 109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable

High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count > 600 x 109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable